Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course

PURPOSE: In peptide receptor radionuclide therapy (PRRT), the bone marrow (BM) is one of the dose-limiting organs. The accepted dose limit for BM is 2 Gy, adopted from (131)I treatment. We investigated the incidence and duration of haematological toxicity and its risk factors in patients treated wit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Nucl Med Mol Imaging
Main Authors: Bergsma, Hendrik, Konijnenberg, Mark W., Kam, Boen L. R., Teunissen, Jaap J. M., Kooij, Peter P., de Herder, Wouter W., Franssen, Gaston J. H., van Eijck, Casper H. J., Krenning, Eric P., Kwekkeboom, Dik J.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4731438/
https://ncbi.nlm.nih.gov/pubmed/26419852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-015-3193-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados